CY1116297T1 - Ενωσεις αρυλοτριαζολιου με αντικαρκινικη δραστικοτητα - Google Patents

Ενωσεις αρυλοτριαζολιου με αντικαρκινικη δραστικοτητα

Info

Publication number
CY1116297T1
CY1116297T1 CY20151100441T CY151100441T CY1116297T1 CY 1116297 T1 CY1116297 T1 CY 1116297T1 CY 20151100441 T CY20151100441 T CY 20151100441T CY 151100441 T CY151100441 T CY 151100441T CY 1116297 T1 CY1116297 T1 CY 1116297T1
Authority
CY
Cyprus
Prior art keywords
arylotrizoli
units
cancer activity
hsp90
inhibition
Prior art date
Application number
CY20151100441T
Other languages
English (en)
Inventor
Giuseppe Giannini
Walter Cabri
Loredana Vesci
Maria Luisa Cervoni
Claudio Pisano
Maurizio Taddei
Serena Ferrini
Original Assignee
Sigma-Tau Research Switzerland S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Research Switzerland S.A. filed Critical Sigma-Tau Research Switzerland S.A.
Publication of CY1116297T1 publication Critical patent/CY1116297T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Η παρούσα εφεύρεση αφορά παράγωγα αρυλοτριαζολίου του Τύπου I, τα οποία έχουν αντικαρκινική δραστικότητα μέσω, ως ενός ενδεχόμενου βιολογικού στόχου, της αναστολής της μοριακής συνοδού πρωτεΐνης θερμικού σοκ 90 (Hsp90). Η εφεύρεση συμπεριλαμβάνει τη χρήση τέτοιων ενώσεων εις την ιατρική σε σχέση με τη νόσο του καρκίνου, όπως επίσης άλλα νοσήματα, όπου μία αναστολή της Hsp90 είναι αποκριτική, και τη φαρμακευτική σύνθεση η οποία περιέχει τέτοιες ενώσεις.
CY20151100441T 2010-12-20 2015-05-15 Ενωσεις αρυλοτριαζολιου με αντικαρκινικη δραστικοτητα CY1116297T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10195949 2010-12-20
EP11805449.3A EP2655345B1 (en) 2010-12-20 2011-12-13 Aryl triazole compounds with antitumoural activity

Publications (1)

Publication Number Publication Date
CY1116297T1 true CY1116297T1 (el) 2017-02-08

Family

ID=43901588

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100441T CY1116297T1 (el) 2010-12-20 2015-05-15 Ενωσεις αρυλοτριαζολιου με αντικαρκινικη δραστικοτητα

Country Status (16)

Country Link
US (1) US9302998B2 (el)
EP (1) EP2655345B1 (el)
JP (1) JP2014501232A (el)
AR (1) AR084361A1 (el)
CY (1) CY1116297T1 (el)
DK (1) DK2655345T3 (el)
ES (1) ES2536980T3 (el)
HR (1) HRP20150450T1 (el)
HU (1) HUE025697T2 (el)
ME (1) ME02144B (el)
PL (1) PL2655345T3 (el)
PT (1) PT2655345E (el)
RS (1) RS53966B1 (el)
SI (1) SI2655345T1 (el)
SM (1) SMT201500115B (el)
WO (1) WO2012084602A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101676208B1 (ko) * 2012-09-17 2016-11-14 에프. 호프만-라 로슈 아게 트라이아졸 카복스아미드 유도체
CN103275023B (zh) * 2013-06-08 2015-10-07 浙江工业大学 1-芳基-1,2,3-三氮唑类化合物及其制备和应用
CN107540624B (zh) * 2016-06-29 2020-06-16 广州市恒诺康医药科技有限公司 热休克蛋白抑制剂及其制备方法和应用
US10975030B2 (en) 2016-10-31 2021-04-13 University Of Kansas Grp94 selective inhibitors and uses thereof
WO2019040869A1 (en) * 2017-08-25 2019-02-28 The Trustees Of Columbia University In The City Of New York INHIBITORS OF IMPORTS OF PURINE IN PARASITES AND USES OF THESE INHIBITORS
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110590686B (zh) * 2019-10-31 2022-10-25 重庆大学 一种氮杂糖基1,2,3-三氮唑核苷化合物及其制备方法和应用
WO2021137665A1 (ko) * 2019-12-30 2021-07-08 이화여자대학교 산학협력단 Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10315570A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Triazolderivate
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0323810D0 (en) 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
ME01498B (me) 2004-11-18 2014-04-20 Synta Pharmaceuticals Corp Jedinjenja triazola koja modulišu aktivnost hsp90
WO2006109846A1 (ja) 2005-04-06 2006-10-19 Takeda Pharmaceutical Company Limited トリアゾール誘導体およびその用途
JP2006306755A (ja) * 2005-04-27 2006-11-09 Nippon Kayaku Co Ltd 新規なピラゾール誘導体とそれを有効成分とするｈｓｐ９０阻害剤
WO2007014198A1 (en) * 2005-07-25 2007-02-01 Synta Pharmaceuticals Corp. 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of poliferative disorders
JP5548364B2 (ja) * 2006-10-03 2014-07-16 日本化薬株式会社 レゾルシノール誘導体の高分子結合体
DK2118077T3 (en) * 2007-02-08 2015-03-09 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 ACTIVITY
JP2011515359A (ja) 2008-03-18 2011-05-19 グラクソ グループ リミテッド 治療用トリアゾールアミド誘導体
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
WO2009139916A1 (en) 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
WO2010017479A1 (en) 2008-08-08 2010-02-11 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity

Also Published As

Publication number Publication date
HRP20150450T1 (hr) 2015-06-05
ES2536980T3 (es) 2015-06-01
EP2655345B1 (en) 2015-02-18
US20140329812A1 (en) 2014-11-06
SMT201500115B (it) 2015-07-09
WO2012084602A1 (en) 2012-06-28
US9302998B2 (en) 2016-04-05
AR084361A1 (es) 2013-05-08
RS53966B1 (en) 2015-08-31
EP2655345A1 (en) 2013-10-30
ME02144B (me) 2015-10-20
SI2655345T1 (sl) 2015-06-30
DK2655345T3 (en) 2015-05-04
PT2655345E (pt) 2015-06-09
PL2655345T3 (pl) 2015-07-31
JP2014501232A (ja) 2014-01-20
HUE025697T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
CY1116297T1 (el) Ενωσεις αρυλοτριαζολιου με αντικαρκινικη δραστικοτητα
CY1123649T1 (el) Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
CY1116100T1 (el) Παραγωγα πυριμιδινονης, η παρασκευη τους και η φαρμακευτικη τους χρηση
CY1119714T1 (el) Ενωσεις αναστολεων
CY1118899T1 (el) Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων
CY1123010T1 (el) Διεγερση γονιδιου τrail με μικρο μοριο απο κανονικα και ογκου κυτταρα ως αντικαρκινικη θεραπεια
BR112018070956A2 (pt) compostos da fórmula, composições farmacêuticas e métodos para distribuir um ácido nucleico para o fígado de um animal e para preparar um composto da fórmula
CY1119200T1 (el) Νεα παραγωγα βενζιμιδαζολιου ως ερ4 ανταγωνιστες
EA201170139A1 (ru) 5-фенилизоксазол-3-карбоксамиды с противоопухолевыми активностями, модулирующие hsp90
CY1119252T1 (el) Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40
CY1118061T1 (el) Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση
BR112016007622A2 (pt) composto, composição farmacêutica, conjugado de ligante-droga, e, método para tratar câncer
CY1117996T1 (el) Genz 112638 για την θεραπευτικη αγωγη της νοσου gaucher ή fabry σε θεραπεια συνδυασμου
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
CY1118682T1 (el) Ενωσεις πυραζολης ως αναστολεις του υποδοχεα σιγμα
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
CY1121910T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει παραγωγο διυδροκιναζολινης με αντιϊικη δραση
CY1116683T1 (el) Φαρμακο το οποιο περιεχει ενα παραγωγο καρβοστυριλιου και δονεπεζιλη για τη θεραπεια της νοσου alzheimer
BR112015004501A2 (pt) derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo
CY1114737T1 (el) Παραγωγα κινοξαλινδιονης
CY1115590T1 (el) Σουλφοξιμινυποκατεστημενα παραγωγα ανιλινοπυριμιδινης ως cdk-αναστολεις, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
CY1114521T1 (el) Ενωσεις βενζαμιδιου χρησιμες ως αναστολεις αποακετυλασων ιστονων